Document Detail

Radiation-induced glioma following CyberKnife® treatment of metastatic renal cell carcinoma: a case report.
Jump to Full Text
MedLine Citation:
PMID:  22943305     Owner:  NLM     Status:  PubMed-not-MEDLINE    
INTRODUCTION: Post-stereotactic radiation-induced neoplasms, although relatively rare, have raised the question of benefit regarding CyberKnife® treatments versus the risk of a secondary malignancy. The incidence of such neoplasms arising in the nervous system is thought to be low, given the paucity of case reports regarding such secondary lesions.
CASE PRESENTATION: Here we describe a case of a 43-year-old Middle Eastern woman with primary clear cell renal cell carcinoma and a metastatic focus to the left brain parenchyma who presented with focal neurologic deficits. Following post-surgical stereotactic radiation in the region of the brain metastasis, the patient developed a secondary high-grade astrocytoma nearly 5 years after the initial treatment.
CONCLUSION: Although the benefit of CyberKnife® radiotherapy treatments continues to outweigh the relatively low risk of a radiation-induced secondary malignancy, knowledge of such risks and a review of the literature are warranted.
Malak Abedalthagafi; Ahmed Bakhshwin
Related Documents :
2053605 - Bilateral congenital cholesteatomas associated with ossicular anomalies: a case report.
21700595 - Is there a place for video associated thoracoscopy for dissecting intramural haematoma ...
24085615 - Madurella mycetomatis as an agent of brain abscess: case report and review of literature.
8705205 - Congenital cns primitive neuroectodermal tumor: case report and review of the literature.
20138565 - Plasmablastic lymphoma of the oral cavity: a review.
11952255 - Giant adrenal myelolipoma.
Publication Detail:
Type:  Journal Article     Date:  2012-09-03
Journal Detail:
Title:  Journal of medical case reports     Volume:  6     ISSN:  1752-1947     ISO Abbreviation:  J Med Case Rep     Publication Date:  2012  
Date Detail:
Created Date:  2012-10-12     Completed Date:  2012-10-15     Revised Date:  2014-07-14    
Medline Journal Info:
Nlm Unique ID:  101293382     Medline TA:  J Med Case Rep     Country:  England    
Other Details:
Languages:  eng     Pagination:  271     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): J Med Case Rep
Journal ID (iso-abbrev): J Med Case Rep
ISSN: 1752-1947
Publisher: BioMed Central
Article Information
Download PDF
Copyright ©2012 Abedalthagafi and Bakhshwin; licensee BioMed Central Ltd.
Received Day: 16 Month: 2 Year: 2012
Accepted Day: 21 Month: 6 Year: 2012
collection publication date: Year: 2012
Electronic publication date: Day: 3 Month: 9 Year: 2012
Volume: 6First Page: 271 Last Page: 271
ID: 3469351
Publisher Id: 1752-1947-6-271
PubMed Id: 22943305
DOI: 10.1186/1752-1947-6-271

Radiation-induced glioma following CyberKnife® treatment of metastatic renal cell carcinoma: a case report
Malak Abedalthagafi1 Email:
Ahmed Bakhshwin1 Email:
1Pathology Department, Georgetown University Hospital, Washington, DC, 20007, USA


Given the advent of new stereotactic radiosurgery techniques, important questions have arisen regarding the risk of secondary malignancy following such treatments. On the basis of previous case reports, the incidence of such a secondary malignancy following CyberKnife® therapy has been estimated at between 0.7% and 1.9% [1,2]. Specifically, reports of post- stereotactic radiation-induced central nervous system (CNS) tumors have been few, and reflect a higher incidence in patients with a predisposition to cancer, such as those with neurofibromatosis. Typically, such a secondary malignancy is thought to arise within a period of 5 to 10 years post-treatment, given a review of the literature involving such patients. Here we present a case of radiation-induced glioma in a patient following treatment with stereotactic radiosurgery for a metastatic renal cell carcinoma focus to the brain. It should be noted that although there remains a notable risk of developing a secondary CNS malignancy following radiotherapy treatment, it is thought that the overall benefits of such treatments outweigh the risk of developing a secondary neoplasm.

Case presentation

A 43-year-old Middle Eastern woman originally presented complaining of a sudden onset of right upper extremity weakness and numbness. A magnetic resonance imaging (MRI) scan of her brain demonstrated a lesion in the left frontal lobe consistent with a possible metastasis, and an abdominal computed tomography showed an 8cm mass in the right kidney. She underwent a radical laparoscopic nephrectomy a month later, and surgical pathology revealed clear cell renal cell carcinoma (Figure 1) of Fuhrman nuclear grade 3 without evidence of metastasis to perinephric fat, the adrenal gland, renal vasculature, or hilar lymph nodes.

Later that same month, the patient also had a left frontal craniotomy performed for metastatic focus resection. Microscopically, the specimen revealed nests of large pleomorphic cells with prominent eosinophilic nuclei that resembled malignant ganglion cells. However, clear cytoplasm was observed in some areas (Figure 2A). Immunohistochemical (IHC) staining was positive for keratin (Figure 2B), vimentin, and CD10, and negative for glial fibrillary acidic protein (GFAP), neurofilament, chromogranin, S100, Human Melanoma Black-45 (HMB-45), smooth muscle actin, desmin, and CD68. The brain mass was therefore diagnosed as poorly-differentiated grade 4 metastatic renal cell carcinoma. Following neurosurgery, the patient underwent whole brain radiotherapy followed by CyberKnife® stereotactic radiosurgery.

A year later, the patient began developing neurological symptoms including right arm tremor, weakness, dizziness, and abnormal sensation on her right cheek. An MRI scan of her brain revealed a large left frontal mass stemming from the insular that subsequently enlarged and grew upwards, creating a midline shift. After 5 months, she underwent resection of the mass. Pathology showed radiation necrosis with sheets of foamy macrophages and gliosis of the surrounding brain tissue with focal perivascular chronic inflammation. IHC staining was negative for keratin, with no evidence of viable tumor cells. IHC staining was positive for CD68 indicating the histiocytic nature of many of the foamy cells.

The patient once again presented with right-sided hemiparesis. Imaging studies showed a left occipital-parietal mass, and surgical resection was completed approximately 4.5 years after her initial craniotomy and brain irradiation. The pathologic appearance of the tissue was consistent with a high-grade astrocytoma, probably glioblastoma multiforme, with areas of necrosis and vascular proliferation (Figures 3A and 3B). IHC was also indicative of glial cells, with staining positive for GFAP and S100 (Figure 3C) but negative for keratin (Figure 3D) and CD10 (Figure 3E). The molecular immunology Borstel-1 (MIB-1) proliferation index was found to be 20% (Figure 3F).


The criteria for a radiation-induced neoplasm as originally outlined by Cahan et al. in 1948 [3] include: 1) the tumor must not be present at the time of irradiation; 2) there must be a prolonged latency period between radiation delivery and tumor development; 3) the tumor must arise in the irradiated region; 4) the tumor must be histologically distinct from the original tumor; and 5) the patient must not have a genetic predisposition to the development of cancer. Our patient’s case seems to fulfill all of these criteria. Extensive imaging was performed at the time of the original diagnosis and no evidence of a lesion was found in the left occipital-parietal area. Although 5 years is the generally accepted minimum latency period for developing a radiation-induced malignancy, cases with shorter latency periods have been reported. This case is complicated by the fact that the patient received both whole brain irradiation as well as Gamma Knife stereosurgery, but the affected secondary location was definitely within the irradiated field. Tumor markers show the histologic disparity between the original brain metastases and the new lesion. Finally, the patient was not known to have any genetic conditions that predispose toward carcinogenesis.

The risk of developing a secondary nervous system cancer, particularly meningiomas, following conventional fractionated radiation exposure has been well established. Studies of the survivors of the atomic bombings of Hiroshima and Nagasaki indicate an increased incidence of meningiomas in this population [4-6]. Epidemiological data derived from child immigrants to Israel after World War II who received radiation for the treatment of tinea capitis showed an increase of up to 6.9-fold in nervous system neoplasms (including meningiomas, gliomas, and nerve sheath tumors) [7]. There has also been some suggestion of greater numbers of meningiomas and gliomas in adults who underwent radiotherapy for pituitary adenomas [8,9]. Finally, experiments on primates given therapeutic doses of fractionated whole-brain radiation resulted in high rates of induction of glioblastoma multiforme [10], and over 100 human cases in which a glioma appeared after radiotherapy have been identified [11]. Nevertheless, the absolute risk of developing a radiation-induced neoplasm after receiving radiotherapy to the CNS remains relatively low and it is generally thought that the overall benefits of the treatment outweigh the negative complication rate of alternative treatments [12].

The risk of oncogenesis due to stereotactic radiosurgery has generally been believed to be lower than that of conventional radiotherapy. Although traditional practices involve low-dose radiation delivered to a high volume of tissue, stereotactic methods allow for high-dose, low-volume radiation with a steep drop in dosage outside the targeted zone. The perception of increased safety in radiosurgery has been supported by an analysis of nearly 5000 English patients who underwent Gamma Knife therapy [13]. This study found only one new case of astrocytoma following radiation in comparison to a predicted incidence of 2.47 in the general population. A major criticism of the study has been that the mean follow-up interval was only just over 6 years. However, the follow-up of over 1200 of the patients was greater than 10 years.


As yet, relatively few case reports of post-stereotactic radiation-induced nervous system tumors have been documented in the literature (Table 1), and some of these involve patients with a genetic predisposition to cancer (e.g. neurofibromatosis 2) who thus do not completely fulfill the Cahan [3] criteria. On the basis of these reports, the incidence of a secondary malignancy following stereotactic radiosurgery has been estimated at between 0.7% and 1.9% [1,2]. In addition, it is believed that, due to the relatively recent advent and dissemination of this technology, relatively more cases may be identified in the near future as a greater population of treated patients reaches the most dangerous latency interval.


Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Authors’ contribution

MA analyzed and interpreted the patient data regarding the histological and immunohistochemical tests, and was a major contributor in writing the manuscript. AB helped in analyzing patient data and follow-up history. Both authors read and approved the final manuscript.


We would like to thank Dr Norio Azumi for his support of this work.

Sheehan J,Yen CP,Steiner L,Sheehan J,Yen CP,Steiner L,Gamma Knife surgery-induced meningioma. Report of two cases and review of the literatureJ NeurosurgYear: 2006105232532910.3171/jns.2006.105.2.32517219842
Brada M,Rajan B,Traish D,Ashley S,Holmes-Sellors PJ,Nussey S,Uttley D,The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomasClin Endocrinol (Oxf)Year: 199338657157810.1111/j.1365-2265.1993.tb02137.x8334743
Cahan WG,Woodard HQ,Higinbotham NL,Stewart FW,Coley BL,Sarcoma arising in irradiated bone; report of 11 casesCancerYear: 19481132910.1002/1097-0142(194805)1:1<3::AID-CNCR2820010103>3.0.CO;2-718867438
Shibata S,Sadamori N,Mine M,Sekine I,Intracranial meningiomas among Nagasaki atomic bomb survivorsLancetYear: 19943448939–894017707997020
Shintani T,Hayakawa N,Hoshi M,Sumida M,Kurisu K,Oki S,Kodama Y,Kajikawa H,Inai K,Kamada N,High incidence of meningioma among Hiroshima atomic bomb survivorsJ Radiat Res (Tokyo)Year: 1999401495710.1269/jrr.40.4910408177
Yonehara S,Brenner AV,Kishikawa M,Inskip PD,Preston DL,Ron E,Mabuchi K,Tokuoka S,Clinical and epidemiologic characteristics of first primary tumors of the central nervous system and related organs among atomic bomb survivors in Hiroshima and Nagasaki, 1958–1995CancerYear: 200410171644165410.1002/cncr.2054315378499
Ron E,Modan B,Boice JD,Alfandary E,Stovall M,Chetrit A,Katz L,Tumors of the brain and nervous system after radiotherapy in childhoodN Engl J MedYear: 1988319161033103910.1056/NEJM1988102031916013173432
Erfurth EM,Bülow B,Mikoczy Z,Svahn-Tapper G,Hagmar L,Is there an increase in second brain tumours after surgery and irradiation for a pituitary tumour?Clin Endocrinol (Oxf)Year: 200155561361610.1046/j.1365-2265.2001.01385.x11894972
Minniti G,Traish D,Ashley S,Gonsalves A,Brada M,Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 yearsJ Clin Endocrinol MetabYear: 200590280080415562021
Lonser RR,Walbridge S,Vortmeyer AO,Pack SD,Nguyen TT,Gogate N,Olson JJ,Akbasak A,Bobo RH,Goffman T,Zhuang Z,Oldfield EH,Induction of glioblastoma multiforme in nonhuman primates after therapeutic doses of fractionated whole-brain radiation therapyJ NeurosurgYear: 20029761378138910.3171/jns.2002.97.6.137812507137
Salvati M,Frati A,Russo N,Caroli E,Polli FM,Minniti G,Delfini R,Radiation- induced gliomas: report of 10 cases and review of the literatureSurg NeurolYear: 2003601606710.1016/S0090-3019(03)00137-X12865017
Muracciole X,Régis J,Radiosurgery and carcinogenesis riskProg Neurol SurgYear: 20082120721318810221
Rowe J,Grainger A,Walton L,Silcocks P,Radatz M,Kemeny A,Risk of malignancy after Gamma Knife stereotactic radiosurgeryNeurosurgeryYear: 2007601606517228253
Comey CH,McLaughlin MR,Jho HD,Martinez AJ,Lunsford LD,Death from a malignant cerebellopontine angle triton tumor despite stereotactic radiosurgery. Case reportJ NeurosurgYear: 1998894653810.3171/jns.1998.89.4.06539761063
Noren G,Long-term complications following Gamma Knife radiosurgery of vestibular schwannomasStereotact Funct NeurosurgYear: 199870suppl 165739782237
Thomsen J,Mirz F,Wetke R,Astrup J,Bojsen-Møller M,Nielsen E,Intracranial sarcoma in a patient with neurofibromatosis type 2 treated with Gamma Knife radiosurgery for vestibular schwannomaAm J OtolYear: 20002133647010.1016/S0196-0709(00)80046-010821550
Yu JS,Yong WH,Wilson D,Black KL,Glioblastoma induction after radiosurgery for meningiomaLancetYear: 200035692411576710.1016/S0140-6736(00)03134-211075777
Kaido T,Hoshida T,Uranishi R,Akita N,Kotani A,Nishi N,Sakaki T,Radiosurgery- induced brain tumor. Case reportJ NeurosurgYear: 2001954710310.3171/jns.2001.95.4.071011596968
Shamisa A,Bance M,Nag S,Tator C,Wong S,Norén G,Guha A,Glioblastoma multiforme occurring in a patient treated with Gamma Knife surgery. Case report and review of the literatureJ NeurosurgYear: 20019458162110.3171/jns.2001.94.5.081611354416
Bari ME,Forster DM,Kemeny AA,Walton L,Hardy D,Anderson JR,Malignancy in a vestibular schwannoma. Report of a case with central neurofibromatosis, treated by both stereotactic radiosurgery and surgical excision, with a review of the literatureBr J NeurosurgYear: 200216328428910.1080/0268869022014888812201399
Shin M,Ueki K,Kurita H,Kirino T,Malignant transformation of a vestibular schwannoma after Gamma Knife radiosurgeryLancetYear: 200236093293091010.1016/S0140-6736(02)09521-112147377
McIver JI,Pollock BE,Radiation-induced tumor after stereotactic radiosurgery and whole brain radiotherapy: case report and literature reviewJ NeurooncolYear: 2004663301515015661
Sanno N,Hayashi S,Shimura T,Maeda S,Teramoto A,Intracranial osteosarcoma after radiosurgery–case reportNeurol Med Chir (Tokyo)Year: 2004441293210.2176/nmc.44.2914959934
Balasubramaniam A,Shannon P,Hodaie M,Laperriere N,Michaels H,Guha A,Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literatureNeuro OncolYear: 20079444745310.1215/15228517-2007-02717704364
Berman EL,Eade TN,Brown D,Weaver M,Glass J,Zorman G,Feigenberg SJ,Radiation-induced tumor after stereotactic radiosurgery for an arteriovenous malformation: case reportNeurosurgeryYear: 2007615E1099 discussion E1099. 10.1227/01.neu.0000303207.92617.4e18091259
Carlson ML,Babovic-Vuksanovic D,Messiaen L,Scheithauer BM,Neff BA,Link MJ,Radiation-induced rhabdomyosarcoma of the brainstem in a patient with neurofibromatosis Type 2J NeurosurgYear: 20101121818710.3171/2009.6.JNS0910519575577


[Figure ID: F1]
Figure 1 

Microscopic image of primary renal cell carcinoma. Hematoxylin and eosin (H&E) stain at 20× magnification.

[Figure ID: F2]
Figure 2 

Microscopic images of brain metastases. (A) H&E stain at 10× magnification. (B) Keratin immunohistochemistry at 40× magnification.

[Figure ID: F3]
Figure 3 

Microscopic images of radiation-induced brain tumor. (A) H&E stain at 10× magnification. (B) H&E stain at 20× magnification. (C) S100 immunohistochemistry at 10× magnification. (D) Keratin staining at 10× magnification. (E) CD10 staining at 10× magnification. (F) Ki-67 staining at 10× magnification. (G) GFAP staining at 10× magnification.

[TableWrap ID: T1] Table 1 

Case reports of secondary malignancy following stereotactic radiosurgery

Reference Patienta Indication for radiation Location of primary lesion Latency period Secondary malignancy Location of secondary lesion
Comey 1998 [14]
Cerebellopontine angle
5 years
Triton tumor
Cerebellopontine angle
Noren 1998 [15]
Cerebellopontine angle
6 years
Triton tumor
Cerebellopontine angle
Thomsen 2000 [16]
Cerebellopontine angle
6 years
Cerebellopontine angle
Yu 2000 [17]
Occipital region
7 years
Occipital lobe
Kaido 2001 [18]
Right parietal lobe
6.5 years
Right parietal lobe
Shamisa 2001 [19]
Cerebellopontine angle
7.5 years
Inferior temporal lobe
Bari 2002 [20]
Cerebellopontine angle
3.5 years
Malignant nerve sheath tumor
Cerebellopontine angle
Salvati 2003 [11]
Right frontal region
13 years
Right frontal, corpus callosum
Shin 2002 [21]
Cerebellopontine angle
6 years
Malignant nerve sheath
Cerebellopontine angle
McIver 2004 [22]
Metastatic melanoma
Left parietal parasagittal region
5.3 years
Anaplastic astrocytoma
Sanno 2004 [23]
Falx cerebri
5 years
Right parietal lobe
Sheehan 2006 [1]
Right basal ganglia
12 years
Assumed meningioma (?)
Right lateral middle cranial fossa
Sheehan 2006 [1]
Right temporal
10 years
Assumed meningioma (?)
Right temporal lobe
Balasubramaniam 2007 [24]
Cerebellopontine angle
5 years
Right temporal lobe
Berman 2007 [25]
Pineal region
9 years
Corpus callosum and/or right parietal lobe
Carlson 2009 [26] 15Fb AVM Bilateral posterior fossae 10 years Rhabdomyosarcoma Inferior right medulla and cerebellomedullary cistern

aage at time of radiation.

bpatient with neurofibromatosis 2.

Abbreviations: AVM arteriovenous malformation, F female, GBM glioblastoma multiforme, M male, VS vestibular schwannoma.

Article Categories:
  • Case Report

Previous Document:  Examining a home environmental strategy to reduce availability of legal products that can be misused...
Next Document:  Involvement of thioredoxin y2 in the preservation of leaf methionine sulfoxide reductase capacity an...